利用CRISPR干扰治疗TGFβ2诱导的高眼压与青光眼
本研究探讨CRISPR干扰系统能否特异性去乙酰化组蛋白并降低小梁网中TGFβ2。研究在人TM细胞中筛选启动子和sgRNA,并在腺病毒介导的TGFβ2诱导高眼压小鼠模型中验证。结果显示该系统可抑制TGFβ2表达并减轻小鼠高眼压,伴随TGFβ2和细胞外基质蛋白水平下降。
要点
- CRISPR干扰系统可在人TM细胞中抑制TGFβ2表达。
- 靶向TGFβ2启动子的sgRNA可抑制Ad5-CMV-TGFβ2诱导的小鼠高眼压。
- 高眼压抑制伴随小鼠眼内TGFβ2和细胞外基质蛋白水平下降。
核心结论
- CRISPR干扰是有用的基因抑制工具,可能成为治疗TGFβ2诱导高眼压的方法。
研究设计与样本
- 研究在人TM细胞中测试不同启动子驱动KRAB-dCAS9的效率并筛选抑制TGFβ2的最佳sgRNA。
- 采用腺病毒介导的TGFβ2诱导高眼压C57BL/6J雌性和雄性小鼠模型在体内验证CRISPR干扰系统效果。
- 使用染色质免疫沉淀-qPCR确定KRAB-dCAS9的结合。
主要发现
- CRISPR干扰系统抑制人TM细胞中TGFβ2表达,合理设计的sgRNA靶向TGFβ2基因启动子。
- 使用靶向Ad5-CMV-TGFβ2病毒载体CMV启动子的sgRNA,慢病毒介导的KRAB-dCAS9和sgRNA表达能抑制C57BL/6J雌性和雄性小鼠眼内Ad5-CMV-TGFβ2诱导的高眼压。
- 高眼压的抑制与小鼠眼内TGFβ2和细胞外基质蛋白水平降低相关。
临床怎么用
- CRISPR干扰可作为针对TGFβ2通路的基因抑制策略,用于治疗TGFβ2诱导的高眼压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide with elevated intraocular pressure (IOP) as the most important risk factor. POAG IOP elevation is due to pathological changes in the trabecular meshwork (TM). Elevated TGFβ2 contributes to these changes and increases IOP. We have shown that histone hyperacetylation is associated with TGFβ2 elevation in the TM. In this study, we determined if clustered regularly interspaced short palindromic repeats (CRISPR) interference could specifically deacetylate histones and decrease TGFβ2 in the TM. METHODS: We tested the efficiency of different promoters in driving KRAB-dCAS9 expression in human TM cells. We also screened and determined the optimal sgRNA sequence in the inhibition of TGFβ2. Chromatin immunoprecipitation-qPCR was used to determine the binding of KRAB-dCAS9. An adenovirus-mediated TGFβ2-induced ocular hypertension (OHT) mouse model was used to determine the effect of the CRISPR interference system in vivo. RESULTS: We found that the CRISPR interference system inhibited TGFβ2 expression in human TM cells, and properly designed sgRNA targeted the promoter of the TGFβ2 gene. Using sgRNA targeting the CMV promoter of the Ad5-CMV-TGFβ2 viral vector, we found that lentivirus-mediated KRAB-dCAS9 and sgRNA expression was able to inhibit Ad5-CMV-TGFβ2-induced OHT in C57BL/6J female and male mice eyes. This inhibition of OHT was associated with decreased levels of TGFβ2 and extracellular matrix proteins in the mouse eye. CONCLUSIONS: Our results indicate that CRISPR interference is a useful tool for gene inhibition and may be a therapeutic approach to treat TGFβ2-induced OHT.
引用
- Rayana NP, Sugali CK, Dai J, et al. Using CRISPR Interference as a Therapeutic Approach to Treat TGFβ2-Induced Ocular Hypertension and Glaucoma. Invest Ophthalmol Vis Sci. 2021. PMID: 34499703. doi:10.1167/iovs.62.12.7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。